nach oben

Pediatric Nephrology

Erschienen in:

15.05.2021 | Educational Review

Role of therapeutic apheresis in the treatment of pediatric kidney diseases

verfasst von: Shweta Shah, Catherine Joseph, Poyyapakkam Srivaths

Erschienen in: Pediatric Nephrology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Therapeutic apheresis utilizes apheresis procedures in the treatment of a variety of conditions including kidney disease. Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartment; however other techniques which adsorb such pathogenic substances or alter the immune profile have been utilized in diseases affecting native and transplanted kidneys. This article discusses the modalities and technical details of therapeutic apheresis and summarizes its role in individual diseases affecting the kidney. Complications related to pediatric apheresis procedures and specifically related to apheresis in kidney disease are also discussed. Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.

Peedin AR, Park YA, Raval JS (2017) Apheresis education in pathology residency. J Clin Apher 32:423–428. https://doi.org/10.1002/jca.21531CrossRefPubMed

McLeod BC (2005) Rationales for therapeutic apheresis. Hematology 10(Suppl 1):203–207. https://doi.org/10.1080/10245330512331390438CrossRefPubMed

Kaplan AA (2008) Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 52:1180–1196. https://doi.org/10.1053/j.ajkd.2008.02.360CrossRefPubMed

Witt V, Stegmayr B, Ptak J, Wikstrom B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J (2008) World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 39:255–260. https://doi.org/10.1016/j.transci.2008.09.001CrossRefPubMed

DeSimone RA, Myers GD, Guest EM, Shi PA (2019) Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis. J Clin Apher 34:487–489. https://doi.org/10.1002/jca.21675CrossRefPubMed

Schinzel H, Berghoff K, Beuermann I, Sauer O, von Mach MA, Weilemann LS (2006) Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience. Transfusion 46:624–629. https://doi.org/10.1111/j.1537-2995.2006.00755.xCrossRefPubMed

Tufan Pekkucuksen N, Sigler KE, Akcan Arikan A, Srivaths P (2020) Tandem plasmapheresis and continuous kidney replacement treatment in pediatric patients. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04769-z

Yokoyama S, Hayashi R, Satani M, Yamamoto A (1985) Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 5:613–622. https://doi.org/10.1161/01.atv.5.6.613CrossRefPubMed

Jang SM, Bahjri K, Lee J, Nabavi S, Abdipour A (2020) Use of angiotensin converting enzyme inhibitors in patients receiving therapeutic plasma exchange with a centrifuge-based apheresis system. Ther Apher Dial. https://doi.org/10.1111/1744-9987.13589

10.

Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J, David M, Duval M, Hume HA, Robitaille N, Belisle A, Champagne MA (2007) Complications of apheresis in children. Transfusion 47:1837–1842. https://doi.org/10.1111/j.1537-2995.2007.01405.xCrossRefPubMed

11.

Sirignano RM, Paden ML, Fasano R, Meyer EK (2018) Epidemiology of therapeutic apheresis with a multidisciplinary approach at a high volume pediatric center. J Clin Apher 33:297–302. https://doi.org/10.1002/jca.21604CrossRefPubMed

12.

Mokrzycki MH, Balogun RA (2011) Therapeutic apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 26:243–248. https://doi.org/10.1002/jca.20303CrossRefPubMed

13.

Lu J, Zhang L, Xia C, Tao Y (2019) Complications of therapeutic plasma exchange: a retrospective study of 1201 procedures in 435 children. Medicine (Baltimore) 98:e18308. https://doi.org/10.1097/MD.0000000000018308CrossRef

14.

Joseph C, Siddiqui S, Shah S, Solomon CH, Srivaths PR (2020) Therapeutic plasma exchange: single-center experience in children with kidney disorders. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04744-8

15.

Paglialonga F, Ardissino G, Consolo S, Ghio L, Belingheri M, Testa S, Biasuzzi A, Edefonti A (2017) Plasma-exchange in pediatric patients: a single-center experience. Minerva Pediatr 69:113–120. https://doi.org/10.23736/S0026-4946.16.04152-9CrossRefPubMed

16.

Cortina G, McRae R, Chiletti R, Butt W (2018) Therapeutic plasma exchange in critically Ill children requiring intensive care. Pediatr Crit Care Med 19:e97–e104. https://doi.org/10.1097/PCC.0000000000001400CrossRefPubMed

17.

Sik G, Demirbuga A, Annayev A, Akcay A, Citak A, Ozturk G (2020) Therapeutic plasma exchange in pediatric intensive care: Indications, results and complications. Ther Apher Dial 24:221–229. https://doi.org/10.1111/1744-9987.13474CrossRefPubMed

18.

Orlin JB, Berkman EM (1980) Partial plasma exchange using albumin replacement: removal and recovery of normal plasma constituents. Blood 56:1055–1059CrossRefPubMed

19.

ABIM Foundation. American Society for apheresis choosing wisely working group (2018) Five Things Patients and Providers Should Question. http://www.choosingwisely.org/societies/american-society-for-apheresis/

20.

Zantek ND, Pagano MB, Rollins-Raval MA, Smith RE, Schmidt AE, Crane JE, Boral LI, Li Y, Svensson AM, Yamada C, Wu Y, Wong ECC (2019) Hemostasis testing and therapeutic plasma exchange: results of a practice survey. J Clin Apher 34:26–32. https://doi.org/10.1002/jca.21666CrossRefPubMed

21.

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher 34:171–354. https://doi.org/10.1002/jca.21705CrossRefPubMed

22.

Gorka J, Polok K, Nowak I, Wludarczyk A, Sydor W, Padjas A, Sznajd J, Szczeklik W, Musial J (2016) Effectiveness of plasmapheresis in ANCA clearance in patients with ANCA-associated vasculitides. Przegl Lek 73:445–447PubMed

23.

Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188. https://doi.org/10.1681/ASN.2007010090CrossRefPubMed

24.

Glockner WM, Sieberth HG, Wichmann HE, Backes E, Bambauer R, Boesken WH, Bohle A, Daul A, Graben N, Keller F et al (1988) Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol 29:1–8PubMed

25.

Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Naniwa T, Sada KE, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Homma S, Arimura Y (2019) Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol 29:119–129. https://doi.org/10.1080/14397595.2018.1500111CrossRefPubMed

26.

Zauner I, Bach D, Braun N, Kramer BK, Funfstuck R, Helmchen U, Schollmeyer P, Bohler J (2002) Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 39:28–35. https://doi.org/10.1053/ajkd.2002.29874CrossRefPubMed

27.

Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, Morrin P, Posen G, Bernstein K et al (1992) A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 20:261–269. https://doi.org/10.1016/s0272-6386(12)80699-8CrossRefPubMed

28.

Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM (1991) Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757–763. https://doi.org/10.1038/ki.1991.272CrossRefPubMed

29.

Walters G, Willis NS, Craig JC (2008) Interventions for renal vasculitis in adults. Cochrane Database Syst Rev 3:CD003232. https://doi.org/10.1002/14651858.CD003232.pub2CrossRef

30.

Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, Hawley CM, Khalidi N, Flossmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suarez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW, PEXIGAS Investigators (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382:622–631. https://doi.org/10.1056/NEJMoa1803537CrossRefPubMedPubMedCentral

31.

Wright E, Dillon MJ, Tullus K (2007) Childhood vasculitis and plasma exchange. Eur J Pediatr 166:145–151. https://doi.org/10.1007/s00431-006-0212-2CrossRefPubMed

32.

Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397. https://doi.org/10.1056/NEJM199108083250604CrossRefPubMed

33.

Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676–1682. https://doi.org/10.1002/pbc.24612CrossRefPubMed

34.

Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE, North American TTP Group (2001) Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 16:19–22. https://doi.org/10.1002/jca.1003CrossRefPubMed

35.

Kaczmarek V, Holle J, Astudillo R, Kempf C, Bufler P, Muller D (2019) Caplacizumab for relapsing thrombotic thrombocytopenic purpura. Pediatr Nephrol 34:1625–1628. https://doi.org/10.1007/s00467-019-04281-zCrossRefPubMed

36.

Blombery P, Scully M (2014) Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 5:15–23. https://doi.org/10.2147/JBM.S46458CrossRefPubMedPubMedCentral

37.

Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807–3815. https://doi.org/10.1093/ndt/gfs394CrossRefPubMed

38.

Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Hartel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Muller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, Konig J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753–759. https://doi.org/10.1093/cid/cis531CrossRefPubMed

39.

Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279. https://doi.org/10.1182/blood-2005-10-007252CrossRefPubMedPubMedCentral

40.

Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A, Indian HUS Registry (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151–1160. https://doi.org/10.1038/ki.2013.373CrossRefPubMed

41.

Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A (2015) Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30:451–457. https://doi.org/10.1007/s00467-014-2948-7CrossRefPubMed

42.

Hingorani S (2016) Renal complications of hematopoietic-cell transplantation. N Engl J Med 374:2256–2267. https://doi.org/10.1056/NEJMra1404711CrossRefPubMed

43.

Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 135:1049–1057. https://doi.org/10.1182/blood.2019004218CrossRefPubMedPubMedCentral

44.

Sartain S, Shubert S, Wu MF, Srivaths P, Teruya J, Krance R, Martinez C (2019) Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience. Biol Blood Marrow Transplant 25:157–162. https://doi.org/10.1016/j.bbmt.2018.08.016CrossRefPubMed

45.

Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen H, Chen F, Armstrong JM, Raisch DW, Bennett CL (2012) Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the southern network on adverse reactions (SONAR). Semin Thromb Hemost 38:845–853. https://doi.org/10.1055/s-0032-1328894CrossRefPubMedPubMedCentral

46.

McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 12:1162–1172. https://doi.org/10.2215/CJN.01380217CrossRefPubMedPubMedCentral

47.

Prasun Giri P, Sinha R, Pal P, Sarkar B (2015) Therapeutic plasma exchange in paediatric SLE: a case series from India. Lupus 24:889–891. https://doi.org/10.1177/0961203315573346CrossRefPubMed

48.

Li QY, Yu F, Zhou FD, Zhao MH (2016) Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine (Baltimore) 95:e3595. https://doi.org/10.1097/MD.0000000000003595CrossRef

49.

Loo CY, Mohamed Said MS, Mohd R, Abdul Gafor AH, Saidin R, Halim NA, Chua MK, Kong NCT (2010) Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 43:335–340. https://doi.org/10.1016/j.transci.2010.10.003CrossRefPubMed

50.

Li M, Wang Y, Qiu Q, Wei R, Gao Y, Zhang L, Wang Y, Zhang X, Chen X (2016) Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis. J Clin Apher 31:375–380. https://doi.org/10.1002/jca.21408CrossRefPubMed

51.

Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, Craig JC, Tong A, Strippoli GFM (2017) Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis 70:324–336. https://doi.org/10.1053/j.ajkd.2016.12.008CrossRefPubMed

52.

Berman H, Rodriguez-Pinto I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G, Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies) (2014) Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". Autoimmun Rev 13:157–162. https://doi.org/10.1016/j.autrev.2013.10.004CrossRefPubMed

53.

Zar T, Kaplan AA (2008) Predictable removal of anticardiolipin antibody by therapeutic plasma exchange (TPE) in catastrophic antiphospholipid antibody syndrome (CAPS). Clin Nephrol 70:77–81. https://doi.org/10.5414/cnp70077CrossRefPubMed

54.

Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, Ingelmo M (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195–207. https://doi.org/10.1097/00005792-199805000-00005CrossRef

55.

Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355–377. https://doi.org/10.1097/00005792-200111000-00002CrossRef

56.

Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, Font J, Asherson RA, European Forum on Antiphospholipid Antibodies (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:2568–2576. https://doi.org/10.1002/art.22018CrossRefPubMed

57.

Fujinaga S, Ohtomo Y, Umino D, Mochizuki H, Murakami H, Shimizu T, Yamashiro Y, Kaneko K (2007) Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy. Pediatr Nephrol 22:899–902. https://doi.org/10.1007/s00467-006-0428-4CrossRefPubMed

58.

Coppo R, Basolo B, Roccatello D, Giachino O, Lajolo D, Martina G, Rollino C, Amore A, Costa M, Piccoli G (1985) Plasma exchange in progressive primary IgA nephropathy. Int J Artif Organs 8(Suppl 2):55–58PubMed

59.

Lai KN, Lai FM, Leung AC, Ho CP, Vallance-Owen J (1987) Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am J Kidney Dis 10:66–70. https://doi.org/10.1016/s0272-6386(87)80014-8CrossRefPubMed

60.

Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M (1999) Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein purpura nephritis in children. Am J Kidney Dis 33:427–433. https://doi.org/10.1016/s0272-6386(99)70178-2CrossRefPubMed

61.

Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, Suzuki S, Suzuki H (2004) Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. Pediatr Nephrol 19:920–923. https://doi.org/10.1007/s00467-004-1514-0CrossRefPubMed

62.

Raina R, Krishnappa V, Sanchez-Kazi C, Quiroga A, Twombley KE, Mathias R, Lo M, Chakraborty R, Mahesh S, Steinke J, Bunchman T, Zaritsky J (2019) Dextran-sulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 7:454. https://doi.org/10.3389/fped.2019.00454CrossRefPubMedPubMedCentral

63.

Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121–1130. https://doi.org/10.1053/j.ajkd.2003.08.012CrossRefPubMed

64.

Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, Triantafyllou E, Bernal W, Auzinger G, Shawcross D, Eefsen M, Bjerring PN, Clemmesen JO, Hockerstedt K, Frederiksen HJ, Hansen BA, Antoniades CG, Wendon J (2016) High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 64:69–78. https://doi.org/10.1016/j.jhep.2015.08.018CrossRefPubMed

65.

Akcan Arikan A, Srivaths P, Himes RW, Tufan Pekkucuksen N, Lam F, Nguyen T, Miloh T, Braun M, Goss J, Desai MS (2018) Hybrid extracorporeal therapies as a bridge to pediatric liver transplantation. Pediatr Crit Care Med 19:e342–e349. https://doi.org/10.1097/PCC.0000000000001546CrossRefPubMed

66.

Schaefer B, Schaefer F, Engelmann G, Meyburg J, Heckert KH, Zorn M, Schmitt CP (2011) Comparison of molecular adsorbents recirculating system (MARS) dialysis with combined plasma exchange and haemodialysis in children with acute liver failure. Nephrol Dial Transplant 26:3633–3639. https://doi.org/10.1093/ndt/gfr115CrossRefPubMed

67.

Koh LJ, Martz K, Blydt-Hansen TD, NAPRTCS Registry Investigators (2019) Risk factors associated with allograft failure in pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Pediatr Transplant 23:e13469. https://doi.org/10.1111/petr.13469CrossRefPubMed

68.

Huang K, Ferris ME, Andreoni KA, Gipson DS (2004) The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Am J Kidney Dis 43:1082–1090. https://doi.org/10.1053/j.ajkd.2004.03.017CrossRefPubMed

69.

Mahesh S, Del Rio M, Feuerstein D, Greenstein S, Schechner R, Tellis V, Kaskel F (2008) Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant 12:682–688. https://doi.org/10.1111/j.1399-3046.2007.00880.xCrossRefPubMed

70.

Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87:1232–1239. https://doi.org/10.1097/TP.0b013e31819f12beCrossRefPubMed

71.

Nehus EJ, Goebel JW, Succop PS, Abraham EC (2013) Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation 96:550–554. https://doi.org/10.1097/TP.0b013e31829c2431CrossRefPubMed

72.

Cleper R, Krause I, Bar Nathan N, Mor M, Dagan A, Weissman I, Frishberg Y, Rachamimov R, Mor E, Davidovits M (2016) Focal segmental glomerulosclerosis in pediatric kidney transplantation: 30 years' experience. Clin Transpl 30:1324–1331. https://doi.org/10.1111/ctr.12825CrossRef

73.

Raina R, Wang J, Sharma A, Chakraborty R (2020) Extracorporeal therapies in the treatment of focal segmental glomerulosclerosis. Blood Purif 49:513–523. https://doi.org/10.1159/000506277CrossRefPubMed

74.

Verghese PS, Rheault MN, Jackson S, Matas AJ, Chinnakotla S, Chavers B (2018) The effect of peri-transplant plasmapheresis in the prevention of recurrent FSGS. Pediatr Transplant 22:e13154. https://doi.org/10.1111/petr.13154CrossRefPubMed

75.

Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M (2011) Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 15:495–501. https://doi.org/10.1111/j.1399-3046.2011.01478.xCrossRefPubMed

76.

Sannomiya A, Murakami T, Koyama I, Nitta K, Nakajima I, Fuchinoue S (2018) Preoperative low-density lipoprotein apheresis for preventing recurrence of focal segmental glomerulosclerosis after kidney transplantation. J Transp Secur 2018:8926786. https://doi.org/10.1155/2018/8926786CrossRef

77.

Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, Clark WF (2016) The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol 17:104. https://doi.org/10.1186/s12882-016-0322-7CrossRefPubMedPubMedCentral

78.

Dall'Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, Zennaro C, Basile G, Montini G, Rivabella L, Cardillo M, Scalamogna M, Ginevri F (1999) Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 34:1048–1055. https://doi.org/10.1016/S0272-6386(99)70010-7CrossRefPubMed

79.

Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K (2001) Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 71:628–633. https://doi.org/10.1097/00007890-200103150-00008CrossRefPubMed

80.

Straatmann C, Kallash M, Killackey M, Iorember F, Aviles D, Bamgbola O, Carson T, Florman S, Vehaskari MV (2014) Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant 18:29–34. https://doi.org/10.1111/petr.12185CrossRefPubMed

81.

Shah L, Hooper DK, Okamura D, Wallace D, Moodalbail D, Gluck C, Koziell A, Zaritsky JJ (2019) LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol 34:2343–2350. https://doi.org/10.1007/s00467-019-04296-6CrossRefPubMed

82.

Pape L, Becker JU, Immenschuh S, Ahlenstiel T (2015) Acute and chronic antibody-mediated rejection in pediatric kidney transplantation. Pediatr Nephrol 30:417–424. https://doi.org/10.1007/s00467-014-2851-2CrossRefPubMed

83.

Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C (2009) Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9:1099–1107. https://doi.org/10.1111/j.1600-6143.2009.02591.xCrossRefPubMed

84.

Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ (2018) The Treatment of antibody-mediated rejection in kidney transplantation: an updated systematic review and meta-analysis. Transplantation 102:557–568. https://doi.org/10.1097/TP.0000000000002049CrossRefPubMed

85.

Charnaya O, Tuchman S, Moudgil A (2018) Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort. Pediatr Transplant 22:e13108. https://doi.org/10.1111/petr.13108CrossRef

86.

Kranz B, Kelsch R, Kuwertz-Broking E, Brocker V, Wolters HH, Konrad M (2011) Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 26:1149–1156. https://doi.org/10.1007/s00467-011-1864-3CrossRefPubMed

87.

Kincaide E, Hitchman K, Hall R, Yamaguchi I, Ding Y, Crowther B (2019) Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients. Pediatr Transplant 23:e13590. https://doi.org/10.1111/petr.13590CrossRefPubMed

88.

Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL (2012) Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 93:603–609. https://doi.org/10.1097/TP.0b013e318245b2afCrossRefPubMedPubMedCentral

89.

Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB (2004) Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 19:79–85. https://doi.org/10.1002/jca.20002CrossRefPubMed

90.

Tobian AA, Shirey RS, Montgomery RA, Cai W, Haas M, Ness PM, King KE (2010) ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 10:1247–1253. https://doi.org/10.1111/j.1600-6143.2010.03103.xCrossRefPubMed

91.

Takahashi K, Saito K (2013) ABO-incompatible kidney transplantation. Transplant Rev (Orlando) 27:1–8. https://doi.org/10.1016/j.trre.2012.07.003CrossRef

92.

Stojanovic J, Adamusiak A, Kessaris N, Chandak P, Ahmed Z, Sebire NJ, Walsh G, Jones HE, Marks SD, Mamode N (2017) Immune desensitization allows pediatric blood group incompatible kidney transplantation. Transplantation 101:1242–1246. https://doi.org/10.1097/TP.0000000000001325CrossRefPubMed

93.

Aikawa A, Kawamura T, Shishido S, Saito K, Takahashi K; ABO-incompatible transplantation committee members (2014) ABO-incompatible living-donor pediatric kidney transplantation in Japan. Clinics (Sao Paulo) 69 Suppl 1:22-27. https://doi.org/10.6061/clinics/2014(sup01)05

94.

Sharma A, Durkan AM (2018) Desensitisation strategies in high-risk children before kidney transplantation. Pediatr Nephrol 33:2239–2251. https://doi.org/10.1007/s00467-017-3882-2CrossRefPubMed

95.

Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL (2016) Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med 374:940–950. https://doi.org/10.1056/NEJMoa1508380CrossRefPubMedPubMedCentral

96.

Pirojsakul K, Desai D, Lacelle C, Seikaly MG (2016) Management of sensitized pediatric patients prior to renal transplantation. Pediatr Nephrol 31:1691–1698. https://doi.org/10.1007/s00467-015-3295-zCrossRefPubMed

97.

Dall'Amico R, Murer L, Montini G, Andreetta B, Zanon GF, Zacchello G, Zacchello F (1998) Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol 9:121–127CrossRefPubMed

Titel: Role of therapeutic apheresis in the treatment of pediatric kidney diseases
verfasst von: Shweta Shah
Catherine Joseph
Poyyapakkam Srivaths
Publikationsdatum: 15.05.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 2/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-021-05093-w

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Role of therapeutic apheresis in the treatment of pediatric kidney diseases

Abstract

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update Pädiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study

What is the cause of kidney dysfunction in a newborn with trisomy 21? Questions

Macroscopic hematuria, facing an uncommon disease: Questions

The impact of a needs-oriented dental prophylaxis program on bacteremia after toothbrushing and systemic inflammation in children, adolescents, and young adults with chronic kidney disease

Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome

A rare cause of arterial hypertension in a child with developmental delay: Answers

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update Pädiatrie